SAB Biotherapeutics (NASDAQ:SABS) Stock Price Down 1.4% – What’s Next?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) shares traded down 1.4% during mid-day trading on Wednesday . The stock traded as low as $3.41 and last traded at $3.48. 321,959 shares changed hands during trading, a decline of 39% from the average session volume of 529,500 shares. The stock had previously closed at $3.53.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. HC Wainwright decreased their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Chardan Capital upped their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Finally, Rodman & Renshaw assumed coverage on SAB Biotherapeutics in a report on Thursday, April 2nd. They set a “buy” rating and a $13.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

SAB Biotherapeutics Stock Down 7.2%

The company has a fifty day moving average of $3.87 and a two-hundred day moving average of $3.74. The company has a market cap of $176.80 million, a PE ratio of -1.50 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, analysts anticipate that SAB Biotherapeutics, Inc. will post -0.72 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC raised its holdings in SAB Biotherapeutics by 434.6% during the 1st quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock valued at $236,000 after buying an additional 50,191 shares during the period. Perceptive Advisors LLC purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $3,004,000. Millennium Management LLC purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $1,212,000. Balyasny Asset Management L.P. purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $1,778,000. Finally, ADAR1 Capital Management LLC raised its holdings in SAB Biotherapeutics by 75.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares during the period. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.